Wednesday, 22 May 2019

You are here

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

A total of 822 patients (563 female, mean age 55 years) were enrolled from 34 National Health Service trusts in England and Scotland, including networks such as the Early Rheumatoid Arthritis Network and the National Institute for Health Research Clinical Research Network. To be enrolled, adult patients had to have clinically apparent synovial swelling of one or more joints or a diagnosis of unclassified arthritis (UA) or new onset of RA (according to 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria.

Key findings included:

  • The median time between symptom onset and rheumatology consult was 27.2 weeks (IQR 14.1-66 weeks).
  • Only 20% of patients were seen within the first 3 months of symptom onset.
  • The median patient delay was 5.4 weeks (IQR 1.4-26.3 weeks).
  • The median general practitioner delay was 6.9 weeks (IQR 2.3–20.3 weeks).
  • Patients had a mean of 4 GP visits before being referred.
  • The median hospital delay was 4.7 weeks (IQR 2.9–7.5 weeks).

Delays were prolonged in patients who purchased over-the-counter medications or used ice/heat packs took longer to seek help than those who did not.

Patients with a palindromic or an insidious symptom onset delayed for longer than those with a non-palindromic or acute onset.

The interval between first consultation with a rheumatologist and initiation of treatment was not measured in this study.

Multiple delays (patient, PCP, hospital, etc) contributed to a longer than expected time from symptom onset to rheumatologic evaluation. Patient education and delays by primary care providers will require interventions to promote more timely referrals.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.

Denosumab Protects Against RA Erosions

Combining denosumab (Prolia) with a conventional disease-modifying antirheumatic drug (DMARD) such as methotrexate showed promise for slowing radiographic damage in rheumatoid arthritis (RA), a manufacturer-sponsored phase III trial called DESIRABLE found.

New ACR/AF Guidelines on JIA Polyarthritis and Uveitis

The American College of Rheumatology (ACR) and the Arthritis Foundation (AF) have released two guidelines on management of juvenile idiopathic arthritis (JIA). The first addresses the treatement of non-systemic polyarthritis, sacroilitis and enthesitis; and the second focuses on JIA associated uveitis - screening, monitoring and treatment.

Shorter Treatment Succeeds in Septic Arthritis

Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.

Among 77 patients randomized to a 4-week course of therapy following surgical drainage for native joint bacterial arthritis, the rate of complete microbiological remission after at least 2 months of follow-up was 97%, according to Ilker Uçkay, MD, of Uniklinik Balgrist in Zurich, Switzerland, and colleagues.

Targeting GM-CSF Works in Rheumatoid Arthritis

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.